Is It Too Late to Buy Ocugen Stock?
As a biotech company without any medicines on the market, it's easy to understand why investors might worry that they're behind on buying shares of Ocugen (NASDAQ: OCGN). As is often the case with biotechs, Ocugen's stock has soared and crashed overnight on several occasions as a result of regulatory rulings and stuttering clinical trial progress.
Is there any clear upward trajectory in sight for people who invest now? Or is Ocugen a has-been stock that's not worth gambling on? Even with a handful of setbacks in plain view, the answers to these two questions are more complicated than they may seem. Let's explore why.
Image source: Getty Images.
Source Fool.com
